Department of Internal Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, United States of America.
Department of Internal Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, United States of America.
Pharmacol Ther. 2020 Oct;214:107612. doi: 10.1016/j.pharmthera.2020.107612. Epub 2020 Jun 17.
AL amyloidosis is a plasma cell disorder leading to the production and extracellular deposition of abnormal immunoglobulin light chains called amyloid. The pathogenesis of the disorder is driven by an abnormal plasma cell clone producing excessive monoclonal immunoglobulin light chains that undergo deposition in various organs of the body such as the heart, kidney, and gastrointestinal tract. The outcome of the disease remains poor with significant morbidity and mortality associated with organ dysfunction. In this review, we describe the current standard diagnostic features, prognosis, and current treatment paradigm of the disease.
AL 淀粉样变性是一种浆细胞疾病,导致异常免疫球蛋白轻链的产生和细胞外沉积,这些轻链被称为淀粉样物质。该疾病的发病机制是由异常浆细胞克隆产生过多的单克隆免疫球蛋白轻链引起的,这些轻链会在身体的各个器官(如心脏、肾脏和胃肠道)中沉积。该疾病的预后仍然很差,与器官功能障碍相关的发病率和死亡率很高。在这篇综述中,我们描述了该疾病的当前标准诊断特征、预后和当前治疗模式。